The European Medicines Agency (EMA) has recommended granting marketing authorization in 2009 for adjunctive therapy for partial-onset seizures, with or without secondary generalisation, in adults with epilepsy. The U.S. Food and Drug Administration (FDA) announced on 2 June 2009 that the drug has been accepted for filing.
Mechanism of action and indications
Eslicarbazepine acetate is a prodrug for S(+)-licarbazepine, the major active metabolite of oxcarbazepine. Its mechanism of action is therefore identical to that of oxcarbazepine.  There may, however, be pharmacokinetic differences. Eslicarbazepine acetate may not produce as high peak levels of (S)-(+)-licarbazepine immediately after dosing as does oxcarbazepine which could theoretically improve tolerability.
The first European PT 101732 .
|This anticonvulsant-related article is a stub. You can help World Heritage Encyclopedia by expanding it.|